The cardioprotective role of probucol against anthracycline and trastuzumab-mediated cardiotoxicity

Journal of the American Society of Echocardiography

Volumn 24, Issue 6, 2011, Pages 699-705

  Walker, Jonathan R ^a   Sharma, Anita ^a   Lytwyn, Matthew ^a   Bohonis, Sheena ^a   Thliveris, James ^a   Singal, Pawan K ^a   Jassal, Davinder S ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Cardiomyopathy; Cardioprotection; Doxorubicin; Probucol; Trastuzumab

Indexed keywords

DOXORUBICIN; PLACEBO; PROBUCOL; TRASTUZUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARDIOTOXICITY; DOPPLER ECHOCARDIOGRAPHY; HEART INJURY; HEART PROTECTION; HISTOPATHOLOGY; MORTALITY; MOUSE; NONHUMAN;

ANALYSIS OF VARIANCE; ANIMALS; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; BLOTTING, WESTERN; BREAST NEOPLASMS; CARDIOMYOPATHIES; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; MICE; PROBUCOL; RANDOM ALLOCATION; SURVIVAL RATE;

EID: 79956368032     PISSN: 08947317     EISSN: 10976795     Source Type: Journal    
DOI: 10.1016/j.echo.2011.01.018     Document Type: Article

References (32)

1. Canadian Cancer Society. Breast cancer statistics. 2010. Available at: http://www.cancer.ca/Canadawide/About%20cancer/Cancer%20statistics/ Stats%20at%20a%20glance/Breast%20cancer.aspx?sc-lang=en. Accessed June 30, 2010.
2. National Cancer Institute. U.S. National Institutes of Health. 2010. Available at: http://www.cancer.gov/cancertopics/types/breast. Accessed June 30, 2010.
3. Plosker GL, Keam SJ. Spotlight on Trastuzumab in the management of HER2-positive metastatic and early-stage breast cancer. BioDrugs 2006;20:259-62. (Pubitemid 44050433)
4. Plosker GL, Keam SJ. Trastuzumab: a review of its use in the management of HER2-positive metastatic and early-stage breast cancer. Drugs 2006;66:449-75.
5. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr., Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84. (Pubitemid 41464706)
6. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72. (Pubitemid 41464705)
7. Perez EA, Rodeheffer R. Clinical cardiac tolerability of trastuzumab. J Clin Oncol 2004;22:322-9. (Pubitemid 41095098)
8. Ewer SM, Ewer MS. Cardiotoxicity profile of trastuzumab. Drug Saf 2008;31:459-67. (Pubitemid 351695459)
9. Guarneri V, Lenihan DJ, Valero V, Durand JB, Broglio K, Hess KR, et al. Longterm cardiac tolerability of trastuzumab inmetastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol 2006;24:4107-15. (Pubitemid 46622286)
10. Wadhwa D, Fallah-Rad N, Grenier D, Krahn M, Fang T, Ahmadie R, et al. Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study. Breast Cancer Res Treat 2009;117:357-64.
11. Gordon LI, Burke MA, Singh AT, Prachand S, Lieberman ED, Sun L, et al. Blockade of the erbB2 receptor induces cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathways. J Biol Chem 2009;284:2080-7.
12. Jassal DS, Han SY, Hans C, Sharma A, Fang T, Ahmadie R, et al. Utility of tissue Doppler and strain rate imaging in the early detection of trastuzumab and anthracycline mediated cardiomyopathy. J Am Soc Echocardiogr 2009;22:418-24.
13. Singal PK, Iliskovic N, Li T, Kumar D. Adriamycin cardiomyopathy: pathophysiology and prevention. FASEB J 1997;11:931-6. (Pubitemid 27425894)
14. Wyatt HL, Meerbaum S, Heng MK, Gueret P, Corday E. Cross-sectional echocardiography. III. Analysis of mathematic models for quantifying volume of symmetric and asymmetric left ventricles. Am Heart J 1980;100:821-8.
15. Sebag IA, Handschumacher MD, Ichinose F, Morgan JG, Hataishi R, Rodrigues AC, et al. Quantitative assessment of regional myocardial function in mice by tissue Doppler imaging: comparison with hemodynamics and sonomicrometry. Circulation 2005;111:2611-6. (Pubitemid 40740860)
16. Sharma AK, Dhingra S, Khaper N, Singal PK. Activation of apoptotic processes during transition from hypertrophy to heart failure in guinea pigs. Am J Physiol Heart Circ Physiol 2007;293:H1384-90.
17. Mackey JR, Clemons M, Côté MA, Delgado D, Dent S, Paterson A, et al. Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group. Curr Oncol 2008;15:24-35.
18. Neilan TG, Blake SL, Ichinose F, Raher MJ, Buys ES, Jassal DS, et al. Disruption of nitric oxide synthase 3 protects against the cardiac injury, dysfunction, and mortality induced by doxorubicin. Circulation 2007;116:506-14. (Pubitemid 47450259)
19. Schaefer A, Klein G, Brand B, Lippolt P, Drexler H, Meyer GP. Evaluation of left ventricular diastolic function by pulsed Doppler tissue imaging in mice. J Am Soc Echocardiogr 2003;16:1144-9. (Pubitemid 37371658)
20. Matoba S, Hwang P, Nguyen T, Shuzukuda Y. Evaluation of pulsed Doppler tissue velocity imaging for assessing systolic function of murine global heart. J Am Soc Echocardiogr 2005;18:148-54. (Pubitemid 40170043)
21. Neilan TG, Jassal DS, Perez-Sanz TM, Raher MJ, Pradhan AD, Buys ES, et al. Tissue Doppler imaging predicts left ventricular dysfunction and mortality in a murine model of cardiac injury. Eur Heart J 2006;27:1868-75. (Pubitemid 44297395)
22. Iliskovic N, Singal PK. Lipid lowering: an important factor in preventing adriamycin-induced heart failure. Am J Pathol 1997;150:727-34. (Pubitemid 27073799)
23. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998;339:900-5. (Pubitemid 28446849)
24. Singal PK, Khaper N, Palace V, Kumar D. The role of oxidative stress in the genesis of heart disease. Cardiovasc Res 1998;40:426-32. (Pubitemid 28557280)
25. Singal PK, Siveski-Iliskovic N, Hill M, Thomas TP, Li T. Combination therapy with probucol prevents adriamycin-induced cardiomyopathy. J Mol Cell Cardiol 1995;27:1055-63.
26. Siveski-Iliskovic N, Kaul N, Singal PK. Probucol promotes endogenous antioxidants and provides protection against adriamycin-induced cardiomyopathy in rats. Circulation 1994;89:2829-35. (Pubitemid 24173705)
27. Crone SA, Zhao YY, Fan L, Gu Y, Minamisawa S, Liu Y, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 2002;8:459-65. (Pubitemid 34546747)
28. Riccio G, Esposito G, Leoncini E, Contu R, Condorelli G, Chiariello M, et al. Cardiotoxic effects, or lack thereof, of anti-ErbB2 immunoagents. FASEB J 2009;23:3171-8.
29. Kumar D, Kirshenbaum LA, Li T, Danelisen I, Singal PK. Apoptosis in adriamycin cardiomyopathy and its modulation by probucol. Antioxid Redox Signal 2001;3:135-45. (Pubitemid 32240636)
30. Olivetti G, Abbi R, Quaini F, Kajstura J, Cheng W, Nitahara JA, et al. Apoptosis in the failing human heart. N Engl J Med 1997;336:1131-41.
31. Birks EJ, Latif N, Enesa K, Folkvang T, Luong Le A, Sarathchandra P, et al. Elevated p53 expression is associated with dysregulation of the ubiquitinproteasome system in dilated cardiomyopathy. Cardiovasc Res 2008;79:472-80.
32. Grazette LP, Boecker W, Matsui T, Semigran M, Force TL, Hajjar RJ, et al. Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy. J Am Coll Cardiol 2004;44:2231-8. (Pubitemid 39576044)